1. Nirsevimab reduces RSV hospitalizations by 82.7%.
2. Study included 8,057 infants, aged ≤12 months.
3. 75.3% efficacy against severe RSV-associated LRTI.
4. Safety data shows no new concerns; mainly Grade 1-2 events reported.
5. Effective across various age and weight categories.
6. Trial funded by Sanofi and AstraZeneca, registered as NCT05437510.
7. Provides a flexible administration schedule aligned with well-baby visits.
8. Ongoing safety follow-up for UK participants for 24 months.

Source: The Lancet Child & Adolescent Health